Passionate about what we do, and having worked together for many years, we have maintained exceptional values within our team, across our unrivalled network of contacts and for our clients.
We are a people business.
Supriya is an experienced communications professional with over 17 years’ of advising clients in financial communications and investor relations, in the UK and overseas. Having worked in both agency and in-house, she has significant expertise in developing and implementing communications strategies to support business and project objectives, and is a media relations specialist with strong entrepreneurial, project and team management skills.
Supriya has implemented global media and investor relations campaigns for clients across healthcare, technology and financial services. She has worked on numerous transactions including fundraisings, M&A and IPOs.
Hollie specialises in providing financial and corporate communications support to a wealth of private and public healthcare companies both in the UK and in Europe.
With over 10 years experience, Hollie has managed and implemented successful IR and PR programmes for her clients, providing support on everything from financial calendar work, investor roadshows and analyst briefings, perception studies and event management to support on major strategic deals and transactions including fundraisings, M&A and IPOs. She also provides media relations expertise to her clients, working across print, online and broadcast media.
Mary has a 20-year successful track record in providing strategic corporate and financial communications to both early- and late-stage healthcare companies.
She has run several high profile PR campaigns and has been instrumental in assisting companies with strategic positioning and fundraising rounds from seed and private financings through IPOs, reverse mergers, as well as numerous follow-on public financings.
Mary has worked with over 100 healthcare clients across Europe and the US including Teva Pharmaceutical, Bayer, Fresenius Medical Care, Kite Pharmaceuticals, UDG Healthcare, Evotec and BioNTech.
Mary has built and led healthcare businesses at several international PR&IR agencies. She started her career at BTG plc where she was involved in the Company’s IPO and the start-up of several new tech and biotech companies.
Eva has 20 years’ experience in fund management and company analysis across the global healthcare sector. She lived in New York for 7 years covering the US. She was recently at Schroder Investment management where she was responsible for the analysis and valuation of publicly listed & about-to-be-listed healthcare companies in medical devices & supplies, diagnostics, biotechnology, pharma, life sciences tools, healthcare distribution, pharmacy benefit management, hospitals & health insurance.
Eva has a PhD in Biochemistry from Bristol University. She is also a fluent German speaker.
Dr Niall Kirk
With a strong scientific background, Stella brings 13 years of experience in life sciences in both academia and startups. Stella was part of the founding team at techspert.io, a Cambridge, UK based technology startup using the power of AI to facilitate knowledge exchange within the life sciences. As Director of Client Relations, she worked with a variety of stakeholders within the sector and gained a unique understanding of the wider industry. Stella has a BSc in Biology, MSc in Biochemistry from Oxford and PhD in Physiology, Development and Neuroscience from Cambridge.
In her role at Optimum, Stella works with the team to build and strengthen its integrated public relations and investor relations offering to clients across the global healthcare industry.
Dr Niall Kirk
It is with great sadness that we have to inform you that our Co-Founder, Niall Kirk, has passed away.
Niall, or Neal, as a few people knew him, was a key figure at Optimum, a Founder, Director, and shareholder. He could always be relied upon for his knowledge of the healthcare sector and in particular, his experience as a former buyside investment manager, a role which he had undertaken for most of his working life. Niall’s contribution to Optimum especially at Board level will be sorely missed, but it is his friendship, candour, sense of humour, forthright opinions and down-to-earth manner which will be impossible to replace.
We will miss Niall immeasurably.
Jonathan has over 25 years’ experience in the City as a sellside analyst at SG Warburg/UBS and Redburn, specialising in the pharmaceutical sector. Latterly, at Redburn, he managed the proprietary research service, in-house and for institutional clients.
Jonathan has established and run several companies with a broad range of products and services.
Based in the US, Bill helps companies to raise finance in the US. He holds the FINRA Uniform Securities Agent license (Series 63) and the Private Securities Offerings Representative license (Series 82) through Finalis Securities LLC, Member FINRA/SIPC. Also a seasoned communications executive and an award-winning, published writer, Bill has a deep background in corporate and financial communications, message development, branding and marketing for life sciences companies and finance industry firms.
Previously Bill held VP and Director-level positions with Brainerd Communicators and Investor Relations Group, respectively. In earlier years he was with a non-profit, ORBIS, spearheading eye surgery programs on-board the “world’s only flying eye hospital” in 20-plus countries.
Charlotte is an experienced communication professional with a deep-rooted interest in life sciences having studied Psychology, Physiology, Microbiology and Anatomy during her time at Edinburgh University.
She was previously an Associate Partner at the financial communications company, Finsbury, where she was among their earliest employees working for eight years at their London offices, during their rapid rise to one of the UK’s leading financial PR companies.
Karl has over 20 years of experience in investor relations – where he spent most of his career at AstraZeneca in R&D and as Head of IR.
Karl trained as a biochemist at Helsinki University and has a PhD from Utrecht University. In 1995 Karl was appointed assistant professor at Leiden University and in 1997 he joined AstraZeneca in Gothenburg. He has spent over 10 years in different R&D roles at AstraZeneca in Sweden and the UK.
In 2007 he moved into Investor Relations at AstraZeneca’s HQ in London to head up the IR function. In 2016 Karl joined Redx Pharma in the UK, as Head of IR and Comms before moving to Kiadis Pharma in Amsterdam.
Manel started his career in healthcare consulting specializing in media relations and investor relations for biotech, medtech and digihealth public and private companies.
He was previously a Research Associate in drug development at Kings College London. He holds a MSc in Molecular Medicine from Imperial College London and a BSc in Cell Biology from Nova University Lisbon.
Our partner in the USA, Burns McClellan, based in New York
Dedicated exclusively to the life sciences industry, offering a comprehensive approach to public and investor relations.
Our partner in the Nordics, Cord Communications, based in Stockholm
Providing expert advice and execution to clients in a wide range of PR-related needs and IR-related issues for both public and non-listed companies.
Optimum Strategic Communications is looking to expand the team in London.
We have openings for a graduate/post graduate level Account Executive and an ambitious Account Manager to join our thriving team.
We are always looking for talented people who can think strategically and work creatively. Whether you’re an established strategic communications practitioner or looking to start your career in investor relations and PR – we want to hear from you.